Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

Table 2 Receptors of Th17-Associated Cytokines. Interleukin-6 is both a target of interleukin-17 and a differentiation factor for Th17 cells. By inducing the production of interleukin-6 or ...

Interleukin-2 (IL-2 ... and overall health when determining reference values and ranges. 19 Table 1 provides an overview of sIL-2R levels in both healthy and diseased individuals.

Table 2 Hazard Ratios for the Primary End Point and Major Secondary End Points in SILCAAT and ESPRIT, According to Treatment Group. In ESPRIT, 159 patients receiving interleukin-2 plus ...

Table 4 Trials with soluble interleukin-1 decoy receptor (rilonacept) Therapeutic vaccines that induce the production of endogenous antibodies targeting epitopes on specific endogenous molecules ...

Interleukin-1 (IL-1 ... Parkinson's disease and stroke (Table 2). For these cases, the evidence is not as extensive as for the experimental models of neuronal injury that have been described.

Woon Geon Shin; Ji Sun Jang; Hyoung Su Kim; Sung Jung Kim; Kyung Ho Kim; Myoung Kuk Jang; Jin Heon Lee; Ha Jung Kim; Hak Yang Kim ...

Researchers have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6 (IL-6). Researchers at The University of ...

In the experiments, researchers used T cells of various genetic backgrounds and also used various biological inhibitors, such as antibodies against interleukins or against interleukin receptors.

Furthermore, the effect of Interleukin-24 (IL-24) on CSCs and CAR-T cell therapy was evaluated. Study: IL-24 improves efficacy of CAR-T cell therapy by targeting stemness of tumor cells.

Woon Geon Shin; Ji Sun Jang; Hyoung Su Kim; Sung Jung Kim; Kyung Ho Kim; Myoung Kuk Jang; Jin Heon Lee; Ha Jung Kim; Hak Yang Kim ...